Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
TRVI
TRVI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TRVI News
Trevi Therapeutics Initiates Two Late-Stage Trials for Haduvio
1d ago
stocktwits
Trevi Therapeutics Initiates Two Phase 3 Trials for Chronic Cough Treatment
1d ago
Newsfilter
Trevi Therapeutics Reports Positive Phase 2b Results for Nalbuphine ER, Over 60% Cough Frequency Reduction at Week 6
Jan 22 2026
PRnewswire
Trevi Therapeutics Reports Significant Cough Frequency Reduction with Nalbuphine ER in Phase 2b Trial
Jan 22 2026
Newsfilter
Trevi Therapeutics Schedules Phase 2 Trials for Chronic Cough in 2026
Jan 08 2026
PRnewswire
Harvest Announces 2025 ETF Reinvested Distributions
Dec 31 2025
Businesswire
Harvest Announces Final Annual Reinvested Distributions for 2025 Tax Year
Dec 31 2025
Newsfilter
Harvest ETFs Updates 2025 Estimated Reinvested Distributions
Dec 22 2025
Businesswire
Inaugural Week of TRVI Options Trading for February 2026
Dec 19 2025
NASDAQ.COM
Trevi Therapeutics Appoints New CFO to Drive Haduvio Development
Dec 04 2025
PRnewswire
Harvest ETFs Reveals Distribution Plans for November 2025
Nov 21 2025
Newsfilter
Leerink Partners Keeps Outperform Rating for Trevi Therapeutics and Increases Price Target to $16
Nov 20 2025
Benzinga
Oppenheimer Upgrades Trevi Therapeutics to Outperform, Increases Price Target to $24
Nov 14 2025
Benzinga
Trevi Therapeutics Aims for Multiple Phase III Trial Launches for Chronic Cough Indications in 2026 as Regulatory Efforts Speed Up
Nov 13 2025
SeekingAlpha
Earnings Report for November 13, 2025: After-Hours Updates on AMAT, BAP, STN, GLOB, TMC, TRVI, PGEN, BZH, OMER, TBN, TOI, AIRJ
Nov 13 2025
NASDAQ.COM
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Nov 13 2025
PRnewswire
Show More News
